Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy plunges to 3Q loss, remains silent on generic Lipitor plans

This article was originally published in Scrip

Executive Summary

There's still no official word on Ranbaxy Laboratories' launch plans for a generic version of Pfizer's money-spinning cholesterol drug Lipitor (atorvastatin) by the month end, even as the Indian firm, now part of Daiichi Sankyo, reported a loss of Rs4.65 billion ($93.9 million) for the third quarter ended 30 September compared with a profit of Rs3.1 billion in the year-ago quarter. Consolidated sales for the quarter, though, increased to $443 million as against $404 million in the same period of the previous year.

You may also be interested in...



Aurobindo-Sandoz End $1bn US Deal

Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.

Takeda Gets New India Chief, Mandate To Broaden Access

Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.

COVID-19, Lockdown Affect Trials in India But Coping Efforts In Hand

The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.

Topics

Related Companies

UsernamePublicRestriction

Register

SC015184

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel